Clinical characteristics of patients in the qRT-PCR validation and FACS analysis to calculate the percentage of ATII cells in CD45-negative lung cells
| Non-COPD (n=5) | COPD (n=9) | p Value | |
|---|---|---|---|
| Age (years) | 66.4±14.4 | 71.9±12.9 | 0.4782 |
| Gender, male/female | 5/0 | 9/0 | |
| Pack-years, median (range) | 61.5 (1.0–160.0) | 50.0 (11.5–127.5) | 0.5078 |
| Lung function | |||
| FEV1/FVC (%) | 81.6±7.4 | 55.9±11.3 | 0.0007 |
| FEV1 (%pred) | 99.9±12.6 | 74.8±20.4 | 0.0292 |
| GOLD stages I/II/III/IV | – | 3/5/1/0 |
All patients underwent lung surgery due to primary lung cancer. Values are the means±SD unless stated otherwise.
ATII, alveolar epithelial type II; COPD, chronic obstructive pulmonary disease; FACS, fluorescence-activated cell sorting; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; qRT-PCR, quantitative reverse transcriptase-PCR.